Hypertension control

World Health Organization - Technical Report Series

Volumn , Issue 862, 1996, Pages

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

EID: 2342584815     PISSN: 05123054     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (120)

1. Hypertension and coronary heart disease: classification and criteria for epidemiological studies. First Report of the Expert Committee on Cardiovascular Diseases and Hypertension. Geneva, World Health Organization, 1959 (WHO Technical Report Series, No. 168).
2. Arterial hypertension and ischaemic heart disease: preventive aspects. Report of a WHO Expert Committee. Geneva, World Health Organization, 1962 (WHO Technical Report Series, No. 231).
3. Arterial hypertension. Report of a WHO Expert Committee. Geneva, World Health Organization, 1978 (WHO Technical Report Series, No. 628).
4. Pickering GW. The nature of essential hypertension. London, Churchill, 1961.
5. MacMahon S et al. Blood pressure, stroke and coronary heart disease. Part 1. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet, 1990, 335:765-774.
6. Evans VG, Rose GA. Hypertension. British medical bulletin, 1971, 27:32-42.
7. Kannel WB, Dawber TR, McGee DL. Perspectives on systolic hypertension: the Framingham Study. Circulation, 1986, 61:1179-1182.
8. MRC Working Party on Mild to Moderate Hypertension. The MRC Mild Hypertension Trial: some subgroup results. In: Strasser T, Ganten D, eds. Mild hypertension: from drug trials to practice. New York, Raven Press, 1987:9-20.
9. Collins R et al. Blood pressure, stroke and coronary heart disease. Part 2. Short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet, 1990, 335:827-838.
10. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Journal of the American Medical Association, 1991, 265:3255-3264.
11. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. British medical journal, 1992, 304:405-412.
12. 1993 guidelines for the management of mild hypertension: memorandum from a WHO/ISH meeting. Bulletin of the World Health Organization, 1993, 71:503-517.
13. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Archives of internal medicine, 1993, 153:154-183.
14. Amery A et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet, 1985, i:1349-1354.
15. Dahlöf B et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet, 1991, 338:1281-1285.
16. MRC Working Party. Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. British medical journal, 1988, 296: 1565-1570.
17. Mancia G. Ambulatory blood pressure monitoring: research and clinical applications. Journal of hypertension, 1990, 8 (Suppl 7):S1-S13.
18. Sega G et al. Ambulatory and home blood pressure normality: the Pamela Study. Journal of cardiovascular pharmacology, 1994, 23 (Suppl.5):S12-S15.
19. Mancia G et al. Alerting reaction and rise in blood pressure during measurement by physician and nurse. Hypertension, 1987, 9:209-215.
20. Julius S et al. White coat hypertension: a follow-up. Clinical experimental hypertension, 1992, A14:45-53.
21. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks: US population data. Archives of internal medicine, 1993, 153:598-615.
22. Kannel WB, Belanger AJ. Epidemiology of heart failure. American heart journal, 1991, 121:951-957.
23. Whelton PK. Epidemiology of hypertension. Lancet, 1994, 344:101-106.
24. Strasser T. Equal blood pressure levels carry different risks in different risk factor combinations. Journal of human hypertension, 1992, 6:261-264.
25. Carvalho JJM et al. Blood pressure in four remote populations in INTERSALT study. Hypertension, 1989, 14:238-246.
26. Alwan AAS. Cardiovascular diseases in the Eastern Mediterranean Region. World health statistics quarterly, 1993, 46(2):97-100.
27. Reddy KS. Cardiovascular diseases in India. World health statistics quarterly, 1993, 46(2):101-107.
28. Hungerbuhler P, Bovet P, Shamlaye C. The cardiovascular disease situation in Seychelles. World health statistics quarterly, 1993, 46(2):108-112.
29. Yao Chonghua, Wu Zhaosu, Wu Yingkai. The changing pattern of cardiovascular disease in China. World health statistics quarterly, 1993, 46(2):113-118.
30. Boedhi-Darmojo R. The pattern of cardiovascular disease in Indonesia. World health statistics quarterly, 1993, 46(2):119-124.
31. Muna WFT. Cardiovascular disorders in Africa. World health statistics quarterly, 1993, 46(2):125-133.
32. Burt V et al. Prevalence of hypertension in adult U.S. populations: results from the third National Health and Nutrition Examination Survey, 1988-91. Hypertension, 1995, 25(3):305-313.
33. Geographical variation in the major risk factors of coronary heart disease in men and women aged 35-64 years. The WHO MONICA Project. World health statistics quarterly, 1988, 41(3/4):115-140.
34. Pickering G. High blood pressure. London, Churchill, 1968.
35. Julius S et al. The association of borderline hypertension with target organ changes and higher coronary risk. Tecumseh Blood Pressure study. Journal of the American Medical Association, 1990, 264:354-358.
36. Williams RR et al. Definition of genetic factors in hypertension: a search for major genes, polygenes, and homogeneous sub-types. Journal of cardiovascular pharmacology, 1988, 12(Suppl. 3):S7-S20.
37. Law CM et al. Initiation of hypertension in utero and its amplification throughout life. British medical journal, 1993, 306:24-27.
38. MacMahon S et al. Obesity and hypertension: epidemiological and clinical issues. European heart journal, 1987, 8:57-70.
39. Modan M, Kalkin H. Hyperinsulinemia or increased sympathetic drive as links for obesity and hypertension. Diabetes care, 1991, 14:470-487.
40. Reaven GM. Role of insulin resistance in human disease (1988 Banting lecture). Diabetes, 1988, 37:1595-1607.
41. Sharma AM. Effects of nonpharmacological intervention on insulin sensitivity. Journal of cardiovascular pharmacology, 1992, 20:S27-S34.
42. Elliott P. Observational studies of salt and blood pressure. Hypertension, 1991, 17(Suppl. 1):103-108.
43. Law MR, Frost CD, Wald NJ. By how much does dietary salt reduction lower blood pressure? I: Analysis of observational data among populations. British medical journal, 1991, 302:811-815.
44. Stamler R. Implications of the INTERSALT study. Hypertension, 1991, 17(Suppl. 1):1017-1020.
45. INTERSALT Cooperative Research Group. INTERSALT: an international study of electrolyte excretion and blood pressure: results for 24-hour urinary sodium and potassium excretion. British medical journal, 1988, 297:319-328.
46. Yamori Y et al. Gene environment interaction in hypertension, stroke and atherosclerosis in experimental models and supportive findings from a worldwide cross-sectional epidemiological survey: a WHO-CARDIAC Study. Clinical experimental pharmacology, physiology supplement, 1992, 20:43-52.
47. Pearce KA, Furberg CD. The primary prevention of hypertension. Cardiovascular risk factors, 1994, 4:147-153.
48. Paffenbarger RS et al. Physical activity and incidence of hypertension in college alumni. American journal of epidemiology, 1983, 117:245-257.
49. Esler M et al. Overflow of catecholamine neurotransmitters to the circulation: source, fate and function. Physiological reviews, 1990, 70:963-986.
50. Anderson EA et al. Elevated sympathetic nerve activity in borderline hypertensive humans. Hypertension, 1989, 14:177-183.
51. Mancia G et al. Evaluating sympathetic activity in human hypertension. Journal of hypertension, 1993, 11(Suppl. 5):S13-S19.
52. Zanchetti A, Mancia G. Cardiovascular reflexes and hypertension. Hypertension, 1991, 18(Suppl. III):13-21.
53. Cowley AW, Roman RJ. The pressure diuresis mechanism in normal and hypertensive states. In: Zanchetti A, Tarazi RC, eds. Pathophysiology of hypertension: regulatory mechanisms. Amsterdam, Elsevier, 1986:295-314 (Handbook of hypertension, Vol. 8).
54. Waeber B, Nussberger J, Brunner HR. The renin angiotensin system: role in experimental and human hypertension. In: Zanchetti A, Tarazi RC, eds. Pathophysiology of hypertension: regulatory mechanisms. Amsterdam, Elsevier, 1986:489-519 (Handbook of hypertension, Vol. 8).
55. Folkow B. Current thinking in hypertension - peripheral vasculature. Blood pressure, 1992, 1(Suppl.I):7-10.
56. Koren MJ et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Annals of internal medicine, 1991, 114:345-352.
57. Korner PI. Some thoughts on pathogenesis, therapy and prevention of hypertension. Blood pressure, 1994, 3:7-17.
58. Lüscher TF et al. Interactions between platelets and the vessel wall. Role of endothelium-derived vasoactive substances. In: Laragh JH, Brenner BM, eds. Hypertension: pathophysiology, diagnosis and management. New York, Raven Press, 1990:637-648.
59. Liu LS et al. Secondary hypertension in the community and among hospitalized hypertensive patients. Acta academiae medicinae sinicae, 1980, 2:236-240.
60. Swales J, ed. Textbook of hypertension. Oxford, Blackwell, 1994.
61. Zanchetti A, Sleight P, Birkenhäger WH. Evaluation of organ damage in hypertension. Journal of hypertension, 1993, 11:875-882.
62. Kannel WB. Left ventricular hypertrophy as a risk factor: the Framingham experience. Journal of hypertension, 1991, 9(Suppl. 2):S3-S9.
63. Levy D et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. New England journal of medicine, 1990, 332:1561-1566.
64. Koren MJ et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Annals of internal medicine, 1991, 114:345-352.
65. Devereux RB. Left ventricular diastolic dysfunction: early diastolic relaxation and late diastolic compliance. Journal of the American College of Cardiology, 1989, 13:337-339.
66. Strauer BE. The hypertensive heart, 3rd ed. Berlin, Springer-Verlag, 1991.
67. Yussuf S, Thom T, Abbott RD. Changes in hypertension treatment and in congestive heart failure mortality in the United States. Hypertension, 1989, 13(Suppl. 1):174-179.
68. Birkenhäger WH, De Leeuw PW. Hypertension, antihypertensive treatment, and kidney. Blood pressure, 1992, 1:201-207.
69. Kannel WB et al. The prognostic significance of proteinuria: the Framingham Study. American heart journal, 1984, 108:1347-1352.
70. Ruilope LM. Proteinuria and renal function. Blood pressure, 1993, 2(Suppl.1): 55-58.
71. Rosansky SJ et al. The association of blood pressure levels and change in renal functions in hypertensive and nonhypertensive subjects. Archives of internal medicine, 1990, 150:2073-2074.
72. Gross F et al. Management of arterial hypertension: a practical guide for the physician and allied health workers. Geneva, World Health Organization, 1984.
73. Task Force on Blood Pressure Control in Children. Report of the Second Task Force on Blood Pressure Control in Children. Pediatrics, 1987, 79:1-25.
74. Layde PM, Beral V, Kay CR. Further analyses of mortality in oral contraceptive users. Royal College of General Practitioners' Oral Contraception Study. Lancet, 1981, i:541-546.
75. Wren BG, Routledge DA. Blood pressure changes: oestrogens in climacteric women. Medical journal of Australia, 1981, 2:528-531.
76. Kincaid-Smith P. Hypertension in pregnancy. Blood pressure, 1994, 3:18-23.
77. Davey DA, McGilliveat I. A classification of the hypertensive disorders of pregnancy. Clinical experimental hypertension, 1986, A5:97-133.
78. Kannel WB. Hypertension and the risk of cardiovascular disease. In: Laragh JH, Brenner BM, eds. Hypertension: pathophysiology, diagnosis and management. New York, Raven Press, 1990:101-117.
79. Epstein M, Sowers JR. Diabetes mellitus and hypertension. Hypertension, 1992, 19:403-418.
80. Rose G. Sick individuals and sick populations. International journal of epidemiology, 1985, 14:32-38.
81. National High Blood Pressure Education Working Group. Report on primary prevention of hypertension. Archives of internal medicine, 1993, 153:186-208.
82. Stevens VJ et al. Weight loss intervention in phase 1 of the Trials of Hypertension Prevention. Archives of internal medicine, 1993, 153:849-858.
83. The Trials of Hypertension Prevention Collaborative Research Group. The effects of nonpharmacologic interventions on blood pressure of persons with high normal levels: results of the trials of hypertension prevention. Phase I. Journal of the American Medical Association, 1992, 267:1213-1220.
84. Puddey IB, Beilin LJ, Vandongen R. Regular alcohol use raises blood pressure in treated hypertensive subjects. Lancet, 1987, i:647-651.
85. Puddey IB et al. Effects of alcohol and caloric restriction on blood pressure and serum lipids in overweight men. Hypertension, 1992, 20:533-541.
86. Paffenbarger RS Jr et al. Physical activity and hypertension. An epidemiological view. Annals of medicine, 1991, 23:319-327.
87. Arakawa K. Hypertension and exercise. Clinical experimental hypertension, 1993, 15:1171-1179.
88. Arroll B, Beaglehole R. Does physical activity lower blood pressure? A critical review of clinical trials. Journal of clinical epidemiology, 1992, 45:439-447.
89. Frost CD, Law MR, Wald NJ. By how much does dietary salt reduction lower blood pressure? II: Analysis of observational data within populations. British medical journal, 1991, 302:815-818.
90. Cutler JA et al. An overview of randomized trials of sodium restriction and blood pressure. Hypertension, 1991, 17(Suppl.1):27-33.
91. Law MR, Frost CD, Wald NJ. By how much does dietary salt reduction lower blood pressure? III: Analysis of data from trials of salt reduction. British medical journal, 1991, 302:819-824.
92. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. British medical journal, 1985, 291:97-104.
93. Manson JE et al. The primary prevention of myocardial infarction. New England journal of medicine, 1992, 326:1406-1416.
94. Stamler R, Stamler J, Gosch FC. Primary prevention of hypertension by nutritional-hygienic means: final results of randomized controlled trial. Journal of the American Medical Association, 1989, 262:1801-1807.
95. Hypertension Prevention Trial Research Group. The hypertension prevention trial. Three year effects of dietary changes on blood pressure. Archives of internal medicine, 1990, 150:153-162.
96. Zanchetti A. Goals of antihypertensive treatment: prevention of cardiovascular events and prevention of organ damage. Blood pressure, 1992, 1:205-211.
97. Lithell H. Insulin resistance and cardiovascular drugs. Clinical experimental hypertension, 1992, A14:151-162.
98. Yusuf S et al. Beta blockade during and after myocardial infarction: An overview of the randomized trials. Progress in cardiovascular diseases, 1985, XXVII: 335-371.
99. Kreft-Jais C, Plouin PF, Tchobroutsky C. Angiotensin converting enzyme inhibition with captopril in human pregnancy. Journal of hypertension, 1987, 5(Suppl.5):S553-S554.
100. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction. New England journal of medicine, 1992, 327:685-691.
101. Pfeffer MA et al. Effects of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trials. New England journal of medicine, 1992, 327:669-677.
102. Dahlöf B, Pennert K and Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients: a meta-analysis of 109 treatment studies. American journal of hypertension, 1992, 5:95-110.
103. Lewis EJ et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. New England journal of medicine, 1993, 329(20): 1456-1462.
104. Chalmers JP. The place of combination therapy in the treatment of hypertension in 1993. Clinical experimental hypertension, 1993, 15(6):1299-1313.
105. Wassertheil-Smoller S et al. The Trial of Antihypertensive Interventions and Management (TAIM) Study. Final results with regard to blood pressure, cardiovascular risk and quality of life. American journal of hypertension, 1992, 5(1):37-44.
106. Siani A et al. Increasing the dietary potassium intake reduces the need for antihypertensive medication. Annals of internal medicine, 1991, 115:753-759.
107. Beard TC et al. Randomised controlled trial of a no-added-sodium diet for mild hypertension. Lancet, 1982, ii:455-458.
108. Neaton JD et al. Treatment of Mild Hypertension Study. Final results. Journal of the American Medical Association, 1993, 270(6):713-724.
109. Cutler JA. Combinations of lifestyle modification and drug treatment in management of mild-moderate hypertension: a review of randomised clinical trials. Clinical experimental hypertension, 1993, 15(6):1193-1204.
110. Grueninger UJ, Goldstein MG, Diffy FD. A conceptual framework for interactive patient education in practice and clinic settings. Journal of human hypertension, 1990, 4(Suppl.1):21-31.
111. Weinstein MC, Stason WB. Hypertension: a policy perspective. Boston, Harvard University Press, 1976.
112. Fletcher A. Pressure to treat and pressure to cost: a review of cost-effectiveness analysis. Journal of hypertension, 1991, 9:193-198.
113. Johannesson M, Jönsson B. A review of cost-effectiveness analyses of hypertension treatment. Pharmaco-Economics, 1992, 1:250-264.
114. Johannesson M et al. The cost-effectiveness of treating hypertension in elderly people - an analysis of the Swedish Trial in Old Patients with Hypertension (STOP Hypertension). Journal of internal medicine, 1993, 234:317-323.
115. Ménard J, Cornu P, Day M. Cost of hypertension treatment and the price of health. Journal of human hypertension, 1992, 6:447-458.
116. The use of essential drugs. Sixth report of the WHO Expert Committee. Geneva, World Health Organization, 1995 (WHO Technical Report Series, No. 850).
117. Ambrosio GB et al. Effects of interventions on community awareness and treatment of hypertension: results of a WHO study. Bulletin of the World Health Organization, 1988, 66(1):107-113.
118. Strasser T, Wilhelmsen L, eds. Assessing hypertension control and management. Hypertension Management Audit Project: a WHO/WHL study. Copenhagen, World Health Organization, 1993 (WHO Regional Publications, European Series No. 47).
119. Wilhelmsen L, Strasser T. WHO/WHL Hypertension Management Audit Project. Journal of human hypertension, 1993, 7:257-263.
120. Rocella EJ, Lenfant C. Considerations regarding the cost and effectiveness of public and patient education programmes. Journal of human hypertension, 1992, 6:463-467.